

108TH CONGRESS  
1ST SESSION

# H. R. 663

To amend title IX of the Public Health Service Act to provide for the improvement of patient safety and to reduce the incidence of events that adversely affect patient safety, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 11, 2003

Mr. BILIRAKIS (for himself, Mr. BROWN of Ohio, Mr. TAUZIN, Mr. DINGELL, Mr. BARTON of Texas, Mr. WAXMAN, Mr. UPTON, Mr. MARKEY, Mr. GREENWOOD, Mr. TOWNS, Mr. BURR, Mr. PALLONE, Mr. WHITFIELD, Mr. GORDON, Mr. NORWOOD, Mr. DEUTSCH, Mr. TERRY, Mr. RUSH, Mr. ROGERS of Michigan, Mr. ENGEL, Mr. WYNN, Ms. MCCARTHY of Missouri, Mr. STRICKLAND, Mrs. CAPPS, Mr. JOHN, and Ms. HARMAN) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend title IX of the Public Health Service Act to provide for the improvement of patient safety and to reduce the incidence of events that adversely affect patient safety, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Patient Safety and  
5 Quality Improvement Act”.

1 **SEC. 2. FINDINGS AND PURPOSES.**

2 (a) FINDINGS.—The Congress finds as follows:

3 (1) In 1999, the Institute of Medicine released  
4 a report entitled “To Err Is Human” that described  
5 medical errors as the 8th leading cause of death in  
6 the United States, with as many as 98,000 people  
7 dying as a result of medical errors each year.

8 (2) To address these deaths and injuries due to  
9 medical errors, the health care system must identify  
10 and learn from such errors so that systems of care  
11 can be improved.

12 (3) Myriad public and private patient safety ini-  
13 tiatives have begun. The Quality Interagency Coordi-  
14 nation Task Force has recommended steps to im-  
15 prove patient safety that may be taken by each Fed-  
16 eral agency involved in health care and activities re-  
17 lating to these steps are ongoing.

18 (4) The Department of Health and Human  
19 Services has initiated several patient safety projects.  
20 The Joint Commission on Accreditation of  
21 Healthcare Organizations issued a patient safety  
22 standard that went into effect on July 1, 2001, and  
23 the peer review organizations are conducting ongoing  
24 studies of clinical performance measurement of care  
25 delivered to beneficiaries under the medicare pro-  
26 gram under title XVIII of the Social Security Act.

1           (5) Several steps can be taken now to improve  
2 patient safety. For example, according to the Cen-  
3 ters for Disease Control and Prevention, hand wash-  
4 ing is the single most important means of preventing  
5 the spread of infection. Repeated studies indicate  
6 that lack of or improper hand washing still contrib-  
7 utes significantly to disease transmission in health  
8 care settings. Working with experts from the private  
9 sector, the Centers for Disease Control and Preven-  
10 tion has drafted “Guidelines for Hand Hygiene in  
11 Healthcare Settings” setting forth recommendations  
12 to promote improved hand hygiene practices and re-  
13 duce transmission of pathogenic microorganisms to  
14 patients and personnel in health care settings.

15           (6) According to the Centers for Disease Con-  
16 trol and Prevention, nosocomial infections affect ap-  
17 proximately 2 million patients annually in acute care  
18 facilities in the United States at an estimated direct  
19 patient care cost of approximately \$3.5 billion each  
20 year.

21           (7) The Congress encourages the continuation  
22 and acceleration of private sector efforts to take im-  
23 mediate steps to improve patient safety and recog-  
24 nizes the need for action in the public sector to com-  
25 plement these efforts.

1           (8) The research on patient safety unequivocally  
2           calls for a learning environment, where pro-  
3           viders will feel safe to report health care errors, in  
4           order to improve patient safety.

5           (9) Voluntary data gathering systems are more  
6           supportive than mandatory systems in creating the  
7           learning environment referred to in paragraph (8) as  
8           stated in the Institute of Medicine’s report.

9           (10) Promising patient safety reporting systems  
10          have been established throughout the United States,  
11          and the best ways to structure and use these sys-  
12          tems are currently being determined, largely through  
13          projects funded by the Agency for Healthcare Re-  
14          search and Quality.

15          (11) Many organizations currently collecting  
16          patient safety information have expressed a need for  
17          protections that will allow them to review protected  
18          information so that they may collaborate in the de-  
19          velopment and implementation of patient safety im-  
20          provement strategies. Currently, the State peer re-  
21          view protections provide inadequate conditions to  
22          allow the sharing of information to promote patient  
23          safety.

24          (12) In 2001, the Institute of Medicine released  
25          a report entitled “Crossing the Quality Chasm” that

1 found that the United States health care system  
2 does not consistently deliver high-quality care to pa-  
3 tients.

4 (b) PURPOSES.—The purposes of this Act are—

5 (1) to encourage a culture of safety and quality  
6 in the United States health care system by providing  
7 for a health care errors reporting system that both  
8 protects information and improves patient safety  
9 and quality of health care; and

10 (2) to ensure accountability by raising stand-  
11 ards and expectations for continuous quality im-  
12 provements in patient safety through the actions of  
13 the Secretary of Health and Human Services.

14 **SEC. 3. AMENDMENTS TO PUBLIC HEALTH SERVICE ACT.**

15 (a) IN GENERAL.—Title IX of the Public Health  
16 Service Act (42 U.S.C. 299 et seq.) is amended—

17 (1) in section 912(c), by inserting “, in accord-  
18 ance with part C,” after “The Director shall”;

19 (2) by redesignating part C as part D;

20 (3) by redesignating sections 921 through 928,  
21 as sections 931 through 938, respectively;

22 (4) in section 938(1) (as so redesignated), by  
23 striking “921” and inserting “931”; and

24 (5) by inserting after part B the following:

1       **“PART C—PATIENT SAFETY IMPROVEMENT**

2       **“SEC. 921. DEFINITIONS.**

3       “In this part:

4               “(1) IDENTIFIABLE INFORMATION.—The term  
5       ‘identifiable information’ means information that is  
6       presented in a form and manner that allows the  
7       identification of any provider, patient, or reporter of  
8       patient safety work product. With respect to pa-  
9       tients, such information includes any individually  
10      identifiable health information as that term is de-  
11      fined in the regulations promulgated pursuant to  
12      section 264(c) of the Health Insurance Portability  
13      and Accountability Act of 1996 (Public Law 104–  
14      191; 110 Stat. 2033).

15              “(2) NONIDENTIFIABLE INFORMATION.—The  
16      term ‘nonidentifiable information’ means informa-  
17      tion that is presented in a form and manner that  
18      prevents the identification of any provider, patient,  
19      or reporter of patient safety work product. With re-  
20      spect to patients, such information must be de-iden-  
21      tified consistent with the regulations promulgated  
22      pursuant to section 264(c) of the Health Insurance  
23      Portability and Accountability Act of 1996 (Public  
24      Law 104–191; 110 Stat. 2033).

25              “(3) PATIENT SAFETY EVALUATION SYSTEM.—  
26      The term ‘patient safety evaluation system’ means a

1 process that involves the collection, management, or  
2 analysis of information for submission to or by a pa-  
3 tient safety organization.

4 “(4) PATIENT SAFETY ORGANIZATION.—The  
5 term ‘patient safety organization’ means a private or  
6 public organization or component thereof that is cer-  
7 tified, through a process to be determined by the  
8 Secretary under section 925, to perform each of the  
9 following activities:

10 “(A) The conduct, as the organization or  
11 component’s primary activity, of efforts to im-  
12 prove patient safety and the quality of health  
13 care delivery.

14 “(B) The collection and analysis of patient  
15 safety work product that is submitted by pro-  
16 viders.

17 “(C) The development and dissemination  
18 of evidence-based information to providers with  
19 respect to improving patient safety, such as rec-  
20 ommendations, protocols, or information re-  
21 garding best practices.

22 “(D) The utilization of patient safety work  
23 product to carry out activities limited to those  
24 described under this paragraph and for the pur-  
25 poses of encouraging a culture of safety and of

1 providing direct feedback and assistance to pro-  
2 viders to effectively minimize patient risk.

3 “(E) The maintenance of confidentiality  
4 with respect to identifiable information.

5 “(F) The provision of appropriate security  
6 measures with respect to patient safety work  
7 product.

8 “(G) The submission of nonidentifiable in-  
9 formation to the Agency consistent with stand-  
10 ards established by the Secretary under section  
11 923(b) for any National Patient Safety Data-  
12 base.

13 “(5) PATIENT SAFETY WORK PRODUCT.—

14 “(A) The term ‘patient safety work prod-  
15 uct’ means any document or communication  
16 (including any information, report, record,  
17 memorandum, analysis, deliberative work, state-  
18 ment, or root cause analysis) that—

19 “(i) except as provided in subpara-  
20 graph (B), is developed by a provider for  
21 the purpose of reporting to a patient safety  
22 organization, and is reported to a patient  
23 safety organization;

24 “(ii) is created by a patient safety or-  
25 ganization; or



1 “(iii) would reveal the deliberations or  
2 analytic process of a patient safety evalua-  
3 tion system (as defined in paragraph (3)).

4 “(B)(i) Patient safety work product de-  
5 scribed in subparagraph (A)(i)—

6 “(I) does not include any separate in-  
7 formation described in clause (ii); and

8 “(II) shall not be construed to include  
9 such separate information merely by rea-  
10 son of inclusion of a copy of the document  
11 or communication involved in a submission  
12 to, or the fact of submission of such a copy  
13 to, a patient safety organization.

14 “(ii) Separate information described in this  
15 clause is a document or communication (includ-  
16 ing a patient’s medical record or any other pa-  
17 tient or hospital record) that is developed or  
18 maintained, or exists, separately from any pa-  
19 tient safety evaluation system.

20 “(C) Information available from sources  
21 other than a patient safety work product under  
22 this section may be discovered or admitted in a  
23 civil or administrative proceeding, if discover-  
24 able or admissible under applicable law.

25 “(6) PROVIDER.—The term ‘provider’ means—

1           “(A) an individual or entity licensed or  
2 otherwise authorized under State law to provide  
3 health care services, including—

4           “(i) a hospital, nursing facility, com-  
5 prehensive outpatient rehabilitation facil-  
6 ity, home health agency, and hospice pro-  
7 gram;

8           “(ii) a physician, physician assistant,  
9 nurse practitioner, clinical nurse specialist,  
10 certified nurse midwife, psychologist, cer-  
11 tified social worker, registered dietitian or  
12 nutrition professional, physical or occupa-  
13 tional therapist, or other individual health  
14 care practitioner;

15           “(iii) a pharmacist; and

16           “(iv) a renal dialysis facility, ambula-  
17 tory surgical center, pharmacy, physician  
18 or health care practitioner’s office, long-  
19 term care facility, behavioral health resi-  
20 dential treatment facility, clinical labora-  
21 tory, or community health center; or

22           “(B) any other person or entity specified  
23 in regulations by the Secretary after public no-  
24 tice and comment.

1 **“SEC. 922. PRIVILEGE FOR PATIENT SAFETY WORK PROD-**  
2 **UCT.**

3 “(a) PRIVILEGE.—Notwithstanding any other provi-  
4 sion of law and subject to subsection (c), patient safety  
5 work product shall not be—

6 “(1) subject to a civil or administrative sub-  
7 poena or order;

8 “(2) subject to discovery in connection with a  
9 civil or administrative proceeding;

10 “(3) subject to disclosure pursuant to section  
11 552 of title 5, United States Code (commonly known  
12 as the Freedom of Information Act), or any other  
13 similar Federal or State law;

14 “(4) required to be admitted as evidence or oth-  
15 erwise disclosed in any State or Federal civil or ad-  
16 ministrative proceeding; or

17 “(5) if the patient safety work product is identi-  
18 fiable information and is received by a national ac-  
19 creditation organization in its capacity as a patient  
20 safety organization—

21 “(A) used by a national accreditation orga-  
22 nization in an accreditation action against the  
23 provider that reported the information;

24 “(B) shared by such organization with its  
25 survey team; or

1           “(C) required as a condition of accredita-  
2           tion by a national accreditation association.

3           “(b) REPORTER PROTECTION.—

4           “(1) IN GENERAL.—A provider may not use  
5           against an individual in an adverse employment ac-  
6           tion described in paragraph (2) the fact that the in-  
7           dividual in good faith reported information—

8           “(A) to the provider with the intention of  
9           having the information reported to a patient  
10          safety organization; or

11          “(B) directly to a patient safety organiza-  
12          tion.

13          “(2) ADVERSE EMPLOYMENT ACTION.—For  
14          purposes of this subsection, an ‘adverse employment  
15          action’ includes—

16          “(A) the failure to promote an individual  
17          or provide any other employment-related benefit  
18          for which the individual would otherwise be eli-  
19          gible;

20          “(B) an adverse evaluation or decision  
21          made in relation to accreditation, certification,  
22          credentialing, or licensing of the individual; and

23          “(C) a personnel action that is adverse to  
24          the individual concerned.

1           “(3) REMEDIES.—Any provider that violates  
2 this subsection shall be subject to a civil monetary  
3 penalty of not more than \$20,000 for each such vio-  
4 lation involved. Such penalty shall be imposed and  
5 collected in the same manner as civil money pen-  
6 alties under subsection (a) of section 1128A of the  
7 Social Security Act are imposed and collected.

8           “(c) DISCLOSURES.—Nothing in this section pro-  
9 hibits any of the following disclosures:

10           “(1) Voluntary disclosure of nonidentifiable in-  
11 formation.

12           “(2) Voluntary disclosure of identifiable infor-  
13 mation by a provider or patient safety organization,  
14 if such disclosure—

15           “(A) is authorized by the provider for the  
16 purposes of improving quality and safety;

17           “(B) is to an entity or person subject to  
18 the requirements of section 264(c) of the  
19 Health Insurance Portability and Accountability  
20 Act of 1996 (Public Law 104–191; 110 Stat.  
21 2033), or any regulation promulgated under  
22 such section; and

23           “(C) is not in conflict with such section or  
24 any regulation promulgated under such section.

1           “(3) Disclosure as required by law by a pro-  
2           vider to the Food and Drug Administration, or on  
3           a voluntary basis by a provider to a federally estab-  
4           lished patient safety program, with respect to an Ad-  
5           ministration-regulated product or activity for which  
6           that entity has responsibility, for the purposes of ac-  
7           tivities related to the quality, safety, or effectiveness  
8           of such Administration-regulated product or activity.

9           “(4) Disclosures of patient safety work product  
10          in accordance with this part by a provider to a pa-  
11          tient safety organization.

12          “(d) EFFECT OF TRANSFER, DISCLOSURE.—The fol-  
13          lowing shall not be treated as a waiver of any privilege  
14          or protection established under this part:

15                 “(1) The transfer of any patient safety work  
16                 product between a provider and a patient safety or-  
17                 ganization.

18                 “(2) Disclosure of patient safety work product  
19                 as described in subsection (c).

20                 “(3) The unauthorized disclosure of patient  
21                 safety work product.

22          “(e) PENALTY.—

23                 “(1) PROHIBITION.—Except as provided in this  
24                 part, and subject to paragraphs (2) and (4), it shall  
25                 be unlawful for any person to disclose patient safety

1 work product in violation of this section, if such dis-  
2 closure constitutes a negligent or knowing breach of  
3 confidentiality.

4 “(2) RELATION TO HIPAA.—The penalty  
5 under paragraph (3) for a disclosure in violation of  
6 paragraph (1) does not apply if the person would be  
7 subject to a penalty under section 264(c) of the  
8 Health Insurance Portability and Accountability Act  
9 of 1996 (Public Law 104–191; 110 Stat. 2033), or  
10 any regulation promulgated under such section, for  
11 the same disclosure.

12 “(3) AMOUNT.—Any person who violates para-  
13 graph (1) shall be subject to a civil monetary penalty  
14 of not more than \$10,000 for each such violation in-  
15 volved. Such penalty shall be imposed and collected  
16 in the same manner as civil money penalties under  
17 subsection (a) of section 1128A of the Social Secu-  
18 rity Act are imposed and collected.

19 “(4) SUBSEQUENT DISCLOSURE.—Paragraph  
20 (1) applies only to the first person that breaches  
21 confidentiality with respect to particular patient  
22 safety work product.

23 “(f) RELATION TO HIPAA.—

24 “(1) IN GENERAL.—For purposes of applying  
25 the regulations promulgated pursuant to section

1       264(c) of the Health Insurance Portability and Ac-  
2       countability Act of 1996 (Public Law 104–191; 110  
3       Stat. 2033)—

4               “(A) patient safety organizations shall be  
5       treated as business associates; and

6               “(B) activities of such organizations de-  
7       scribed in section 921(4) in relation to a pro-  
8       vider are deemed to be health care operations  
9       (as defined in such regulations) of the provider.

10              “(2) RULE OF CONSTRUCTION.—Nothing in  
11       this section shall be construed to alter or affect the  
12       implementation of such regulations or such section  
13       264(c).

14              “(g) NO LIMITATION OF OTHER PRIVILEGES.—  
15       Nothing in this section shall be construed to affect privi-  
16       leges, including peer review and confidentiality protec-  
17       tions, that are otherwise available under Federal or State  
18       laws.

19              “(h) NO LIMITATION ON CONTRACTS.—Nothing in  
20       this section shall be construed to limit the power of a pro-  
21       vider and a patient safety organization, or a patient safety  
22       organization and the Agency or any National Patient  
23       Safety Database, consistent with the provisions of this Act  
24       and other applicable law, to enter into a contract requiring



1 greater confidentiality or delegating authority to make an  
2 authorized disclosure.

3 “(i) RELATION TO STATE REPORTING REQUIRE-  
4 MENTS.—Nothing in this part shall be construed as pre-  
5 empting or otherwise affecting any State law requiring a  
6 provider to report information, including information de-  
7 scribed in section 921(5)(B), that is not patient safety  
8 work product.

9 “(j) CONTINUATION OF PRIVILEGE.—Patient safety  
10 work product of an organization that is certified as a pa-  
11 tient safety organization shall continue to be privileged  
12 and confidential, in accordance with this section, if the or-  
13 ganization’s certification is terminated or revoked or if the  
14 organization otherwise ceases to qualify as a patient safety  
15 organization.

16 “(k) REPORTS ON STRATEGIES TO IMPROVE PA-  
17 TIENT SAFETY.—

18 “(1) DRAFT REPORT.—Not later than the date  
19 that is 18 months after any National Patient Safety  
20 Database is operational, the Secretary, in consulta-  
21 tion with the Director, shall prepare a draft report  
22 on effective strategies for reducing medical errors  
23 and increasing patient safety. The draft report shall  
24 include any measure determined appropriate by the  
25 Secretary to encourage the appropriate use of such

1 strategies, including use in any federally funded pro-  
2 grams. The Secretary shall make the draft report  
3 available for public comment and submit the draft  
4 report to the Institute of Medicine for review.

5 “(2) FINAL REPORT.—Not later than 1 year  
6 after the date described in paragraph (1), the Sec-  
7 retary shall submit a final report to the Congress  
8 that includes, in an appendix, any findings by the  
9 Institute of Medicine concerning research on the  
10 strategies discussed in the draft report and any  
11 modifications made by the Secretary based on such  
12 findings.

13 **“SEC. 923. NATIONAL DATABASE.**

14 “(a) AUTHORITY.—

15 “(1) IN GENERAL.—In conducting activities  
16 under this part, the Secretary shall provide for the  
17 establishment and maintenance of a database to re-  
18 ceive relevant nonidentifiable patient safety work  
19 product, and may designate entities to collect rel-  
20 evant nonidentifiable patient safety work product  
21 that is voluntarily reported by patient safety organi-  
22 zations upon the request of the Secretary. Any data-  
23 base established or designated under this paragraph  
24 may be referred to as a ‘National Patient Safety  
25 Database’.

1           “(2) USE OF INFORMATION.—Information re-  
2           ported to any National Patient Safety Database  
3           shall be used to analyze national and regional statis-  
4           tics, including trends and patterns of health care er-  
5           rors. The information resulting from such analyses  
6           may be included in the annual quality reports pre-  
7           pared under section 913(b)(2).

8           “(3) ADVISORY ROLE.—The Secretary shall  
9           provide scientific support to patient safety organiza-  
10          tions, including the dissemination of methodologies  
11          and evidence-based information related to root  
12          causes and quality improvement.

13          “(b) STANDARDS.—In establishing or designating a  
14          database under subsection (a)(1), the Secretary shall, in  
15          consultation with representatives of patient safety organi-  
16          zations, the provider community, and the health informa-  
17          tion technology industry, determine common formats for  
18          the voluntary reporting of nonidentifiable patient safety  
19          work product, including necessary elements, common and  
20          consistent definitions, and a standardized computer inter-  
21          face for the processing of the work product. To the extent  
22          practicable, such standards shall be consistent with the  
23          administrative simplification provisions of part C of title  
24          XI of the Social Security Act.

1 “(c) CERTAIN METHODOLOGIES FOR COLLECTION.—

2 The Secretary shall ensure that the methodologies for the  
3 collection of nonidentifiable patient safety work product  
4 for any National Patient Safety Database include the  
5 methodologies developed or recommended by the Patient  
6 Safety Task Force of the Department of Health and  
7 Human Services.

8 “(d) FACILITATION OF INFORMATION EXCHANGE.—

9 To the extent practicable, the Secretary may facilitate the  
10 direct link of information between providers and patient  
11 safety organizations and between patient safety organiza-  
12 tions and any National Patient Safety Database.

13 “(e) RESTRICTION ON TRANSFER.—Only nonidentifi-

14 able information may be transferred to any National Pa-  
15 tient Safety Database.

16 **“SEC. 924. TECHNICAL ASSISTANCE.**

17 “(a) IN GENERAL.—The Secretary, acting through  
18 the Director, may—

19 “(1) provide technical assistance to patient  
20 safety organizations, and to States with reporting  
21 systems for health care errors; and

22 “(2) provide guidance on the type of data to be  
23 voluntarily submitted to any National Patient Safety  
24 Database.



1       menting standards as determined by the Secretary  
2       through rulemaking) not less often than every 3  
3       years, as determined by the Secretary.

4               “(4) Revocation of any such certification by the  
5       Secretary or other such governmental organization  
6       that issued the certification, upon a showing of  
7       cause.

8               “(c) CRITERIA.—A patient safety organization must  
9       meet the following criteria as conditions of certification:

10              “(1) The mission of the patient safety organiza-  
11       tion is to conduct activities that are to improve pa-  
12       tient safety and the quality of health care delivery  
13       and is not in conflict of interest with the providers  
14       that contract with the patient safety organization.

15              “(2) The patient safety organization has appro-  
16       priately qualified staff, including licensed or certified  
17       medical professionals.

18              “(3) The patient safety organization, within any  
19       2 year period, contracts with more than 1 provider  
20       for the purpose of receiving and reviewing patient  
21       safety work product.

22              “(4) The patient safety organization is not a  
23       component of a health insurer or other entity that  
24       offers a group health plan or health insurance cov-  
25       erage.

1           “(5) The patient safety organization is man-  
2           aged, controlled, and operated independently from  
3           any provider that contracts with the patient safety  
4           organization for reporting patient safety work prod-  
5           uct.

6           “(6) To the extent practical and appropriate,  
7           the patient safety organization collects patient safety  
8           work product from providers in a standardized man-  
9           ner that permits valid comparisons of similar cases  
10          among similar providers.

11          “(d) ADDITIONAL CRITERIA FOR COMPONENT ORGA-  
12          NIZATIONS.—If a patient safety organization is a compo-  
13          nent of another organization, the patient safety organiza-  
14          tion must, in addition to meeting the criteria described  
15          in subsection (c), meet the following criteria as conditions  
16          of certification:

17               “(1) The patient safety organization maintains  
18               patient safety work product separately from the rest  
19               of the organization, and establishes appropriate se-  
20               curity measures to maintain the confidentiality of  
21               the patient safety work product.

22               “(2) The patient safety organization does not  
23               make an unauthorized disclosure under this Act of  
24               patient safety work product to the rest of the orga-  
25               nization in breach of confidentiality.

1           “(3) The mission of the patient safety organiza-  
2           tion does not create a conflict of interest with the  
3           rest of the organization.”.

4           (b) AUTHORIZATION OF APPROPRIATIONS.—Section  
5           937 of the Public Health Service Act (as redesignated by  
6           subsection (a)) is amended by adding at the end the fol-  
7           lowing:

8           “(e) PATIENT SAFETY AND QUALITY IMPROVE-  
9           MENT.—For the purpose of carrying out part C, there are  
10          authorized to be appropriated such sums as may be nec-  
11          essary for each of the fiscal years 2004 through 2013.”.

12       **SEC. 4. PROMOTING THE DIFFUSION AND INTEROPER-**  
13                       **ABILITY OF INFORMATION TECHNOLOGY SYS-**  
14                       **TEMS INVOLVED WITH HEALTH CARE DELIV-**  
15                       **ERY.**

16          (a) VOLUNTARY STANDARDS.—

17               (1) IN GENERAL.—Not later than 18 months  
18               after the date of the enactment of this Act, the Sec-  
19               retary of Health and Human Services (in this sec-  
20               tion referred to as the “Secretary”) shall—

21                       (A) develop or adopt voluntary national  
22                       standards that promote the interoperability of  
23                       information technology systems involved with  
24                       health care delivery, including but not limited to  
25                       computerized physician order entry;



1 (B) in developing or adopting such stand-  
2 ards, take into account—

3 (i) the ability of such systems to cap-  
4 ture and aggregate clinically specific data  
5 to enable evidence-based medicine and  
6 other applications that promote the elec-  
7 tronic exchange of patient medical record  
8 information; and

9 (ii) the cost that meeting such stand-  
10 ards would have on providing health care  
11 in the United States and the increased effi-  
12 ciencies in providing such care achieved  
13 under the standards;

14 (C) in developing or adopting such stand-  
15 ards and to the extent practicable, test the effi-  
16 cacy, usability, and scalability of proposed inter-  
17 operability standards within a variety of clinical  
18 settings, including an urban academic medical  
19 center, a rural hospital, a community health  
20 center, and a community hospital; and

21 (D) submit a report to the Congress con-  
22 taining recommendations on such standards.

23 (2) CONSULTATION.—In developing or adopting  
24 standards under paragraph (1)(A), the Secretary  
25 shall consider the recommendations of the National

1 Committee on Vital Health Statistics for the stand-  
2 ardization of message formatting, coding, and vocab-  
3 ulary for interoperability of information technology  
4 systems involved with health care delivery. The Sec-  
5 retary shall consult with representatives of the  
6 health information technology industry and the pro-  
7 vider community who are involved with the develop-  
8 ment of interoperability standards.

9 (b) UPDATES.—The Secretary shall provide for the  
10 ongoing review and periodic updating of the standards de-  
11 veloped under subsection (a).

12 **SEC. 5. REQUIRED USE OF PRODUCT IDENTIFICATION**  
13 **TECHNOLOGY.**

14 The Federal Food, Drug, and Cosmetic Act (21  
15 U.S.C. 301 et seq.) is amended—

16 (1) in section 502, by adding at the end the fol-  
17 lowing:

18 “(w) If it is a drug or biological product, unless it  
19 includes a unique product identifier for the drug or bio-  
20 logical product as required by regulations under section  
21 510(q).”; and

22 (2) in section 510, by adding at the end the fol-  
23 lowing:

24 “(q)(1) The Secretary shall issue, and may periodi-  
25 cally revise, regulations requiring the manufacturer of any

1 drug or biological product that is subject to regulation by  
2 the Food and Drug Administration, or the packager or  
3 labeler of a drug or biological product that is subject to  
4 regulation by the Food and Drug Administration, to in-  
5 clude a unique product identifier on the packaging of the  
6 drug or biological product.

7 “(2) For purposes of this subsection, the term  
8 ‘unique product identifier’ means an identification that—

9 “(A) is affixed by the manufacturer, labeler, or  
10 packager to each drug or biological product de-  
11 scribed in paragraph (1) at each packaging level;

12 “(B) uniquely identifies the item and meets the  
13 standards required by this section; and

14 “(C) can be read by a scanning device or other  
15 technology acceptable to the Secretary.

16 “(3) A unique product identifier required by regula-  
17 tions issued or revised under paragraph (1) shall be based  
18 on—

19 “(A) the National Drug Code maintained by  
20 the Food and Drug Administration;

21 “(B) commercially accepted standards estab-  
22 lished by organizations that are accredited by the  
23 American National Standards Institute, such as the  
24 Health Industry Business Communication Council or  
25 the Uniform Code Council; or

1           “(C) other identification formats that the Sec-  
2           retary deems appropriate.

3           “(4) The Secretary may, at the Secretary’s discre-  
4           tion, waive the requirements of this section, or add addi-  
5           tional provisions that are necessary to safeguard the pub-  
6           lic health.”.

○